Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Demographic and baseline characteristics of the study population

From: Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial

 

Intervention period (n = 590)

Control period (n = 724)

P value

Male sex

338 (57.3)

439 (60.6)

0.22

Age, mean ± SD

66.1 ± 13.3

65.8 ± 13.5

0.69

Underlying diseases

   

 Solid cancer

143 (24.2)

183 (25.3)

0.66

 Hematologic malignancy

33 (5.6)

47 (6.5)

0.46

 Solid organ transplant

34 (5.8)

49 (6.8)

0.46

 Hematopoietic stem cell transplant

9 (1.5)

15 (2.1)

0.46

 End-stage renal disease, on dialysis

33 (5.6)

36 (5.0)

0.62

Antibiotics used within the previous 3 months

   

 Cefazolin

73 (12.4)

79 (10.9)

0.41

 3rd cephalosporin

95 (16.1)

143 (19.8)

0.09

 Piperacillin/tazobactam

177 (30.0)

198 (27.3)

0.29

 Fluoroquinolone

168 (28.5)

198 (27.3)

0.65

 Carbapenem

90 (15.3)

120 (16.6)

0.52

 Glycopeptide (vancomycin or teicoplanin)

113 (19.2)

142 (19.6)

0.83

 Other

180 (30.5)

210 (29.0)

0.55

ICU stay, days (mean ± SD)

11.0 ± 12.0

11.2 ± 13.7

0.73

  1. The data are shown as no. (%) unless otherwise indicated
  2. SD standard deviation